[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408866":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":40,"responsibleParty":105,"collaborators":108,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":10,"studyType":124,"phases":10,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"University of Split, School of Medicine","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Relapsing-remmitting MS group treated with corticosteroids",null,"1. Clinical testing\n2. Neurophysiological examination (TMS, EMNG)\n3. Psychomotor examination\n4. Neuropsychological evaluation\n5. Flow cytometry\n6. ELISA",[13],"Diagnostic Test: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA",{"label":15,"type":10,"description":16,"interventionNames":17},"Relapsing-remmitting MS group treated with immunomodulation","1\\. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy control group","5\\. Flow cytometry",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA","All groups will not have the same intervention. Interventions are listed and numbered for each group.",[19,9,15],[29],{"name":30,"affiliation":5,"role":31},"Maja Rogić Vidaković, MSc, PhD","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","0038598508210","maja.rogic@mefst.hr",{"name":38,"role":34,"phone":10,"phoneExt":10,"email":39},"Sanda Pavelin, MD, PhD","spavelin@gmail.com",[41],{"facility":42,"status":43,"city":44,"state":10,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of Split School of Medicine","RECRUITING","Split","21000","Croatia","HR",{"type":49,"coordinates":50},"Point",[51,52],16.43915,43.50891,{"lat":52,"lon":51},[55,59,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,91,93,95,97,99,101,103],{"name":56,"role":34,"phone":57,"phoneExt":10,"email":58},"Lana Bošnjak, PhD","+385 21 557929","lana.barac@mefst.hr",{"name":60,"role":61,"phone":10,"phoneExt":10,"email":10},"Anita Markotić, PhD","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":10,"phoneExt":10,"email":10},"Meri Matijaca, MD, PhD",{"name":65,"role":61,"phone":10,"phoneExt":10,"email":10},"Nikolina Režić Mužinić, PhD",{"name":67,"role":61,"phone":10,"phoneExt":10,"email":10},"Benjamin Benzon, PhD",{"name":69,"role":61,"phone":10,"phoneExt":10,"email":10},"Angela Mastelić, PhD",{"name":71,"role":61,"phone":10,"phoneExt":10,"email":10},"Ana Jerković, Mag. psych",{"name":73,"role":61,"phone":10,"phoneExt":10,"email":10},"Ivan Buljan, PhD",{"name":75,"role":61,"phone":10,"phoneExt":10,"email":10},"Vana Košta, MD, PhD",{"name":77,"role":61,"phone":10,"phoneExt":10,"email":10},"Nikolina Ivica Miše, MD",{"name":79,"role":61,"phone":10,"phoneExt":10,"email":10},"Ana Poljičanin, MD, PhD",{"name":81,"role":61,"phone":10,"phoneExt":10,"email":10},"Mario Mihalj, MD, PhD",{"name":83,"role":61,"phone":10,"phoneExt":10,"email":10},"Ana Ćurković Katić, MD",{"name":85,"role":61,"phone":10,"phoneExt":10,"email":10},"Ivica Bilić, MD,Phd",{"name":87,"role":61,"phone":10,"phoneExt":10,"email":10},"Zoran Đogaš, MD, PhD",{"name":89,"role":61,"phone":10,"phoneExt":10,"email":10},"Krešimir Dolić, MD, PhD",{"name":38,"role":61,"phone":10,"phoneExt":10,"email":10},{"name":92,"role":61,"phone":10,"phoneExt":10,"email":10},"Ljubica Trogrlić, med.techn.",{"name":94,"role":61,"phone":10,"phoneExt":10,"email":10},"Joško Šoda, PhD",{"name":96,"role":61,"phone":10,"phoneExt":10,"email":10},"Igor Vujović, PhD",{"name":98,"role":61,"phone":10,"phoneExt":10,"email":10},"Nataša Šimić, PhD",{"name":100,"role":61,"phone":10,"phoneExt":10,"email":10},"Matilda Nikolić Ivanišević, PhD",{"name":102,"role":61,"phone":10,"phoneExt":10,"email":10},"Sanda Pavelin, PhD",{"name":104,"role":61,"phone":10,"phoneExt":10,"email":10},"Antonia Bralić, MD",{"type":31,"investigatorFullName":106,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Maja Rogić Vidaković","Research Associate Maja Rogić Vidaković",[109],{"name":110,"class":6},"University Hospital of Split","100408866","investigation-of-subclinical-markers-of-multiple-sclerosis-100408866",false,"NCT04604041","Investigation of Subclinical Markers of Multiple Sclerosis","SUBCLIN-MS","Inclusion Criteria:\n\n* Subjects with a documented diagnosis of relapsing-remitting MS according to the Mc Donald criteria (2005) and with EDSS achievement of 0-3.5 according to the modified Kurtzke's EDSS (Expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis\n\nExclusion Criteria:\n\n* Patients with metals in the body (e.g. pacemaker, dentures)\n* Patients with new pregnancies (verbally confirmed)\n* Patients with new head trauma\n* Subjects unwilling to sign a consent or follow study procedures","ALL","18 Years","65 Years",{"count":122,"type":123},50,"ESTIMATED","OBSERVATIONAL","Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type.\n\nThe objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting MS patients, and in patients with relapsing-remitting MS treated with immunomodulation. The results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting MS.",[127,128],"Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis",[130,131,132,133,134,135,136],"multiple sclerosis","relapsing remitting","TMS","Cytometry","ELISA","corticosteroids","immunomodulation","2023-09-28",{"date":139,"type":140},"2023-10-02","ACTUAL",{"date":142,"type":140},"2020-11-23",{"date":144,"type":123},"2028-12-31",{"name":5,"class":6},1]